Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioventus (BVS) Current Assets (2020 - 2025)

Bioventus (BVS) has disclosed Current Assets for 6 consecutive years, with $272.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Current Assets fell 1.0% year-over-year to $272.8 million, compared with a TTM value of $272.8 million through Dec 2025, down 1.0%, and an annual FY2025 reading of $272.8 million, down 1.0% over the prior year.
  • Current Assets was $272.8 million for Q4 2025 at Bioventus, down from $280.9 million in the prior quarter.
  • Across five years, Current Assets topped out at $308.9 million in Q2 2024 and bottomed at $245.4 million in Q2 2022.
  • Average Current Assets over 5 years is $271.1 million, with a median of $271.6 million recorded in 2021.
  • The sharpest move saw Current Assets increased 25.78% in 2023, then decreased 13.85% in 2024.
  • Year by year, Current Assets stood at $263.1 million in 2021, then increased by 3.6% to $272.6 million in 2022, then decreased by 1.68% to $268.0 million in 2023, then grew by 2.84% to $275.6 million in 2024, then decreased by 1.0% to $272.8 million in 2025.
  • Business Quant data shows Current Assets for BVS at $272.8 million in Q4 2025, $280.9 million in Q3 2025, and $275.2 million in Q2 2025.